000168171 001__ 168171
000168171 005__ 20260202145620.0
000168171 0247_ $$2doi$$a10.1046/j.1523-5378.1998.08039.x
000168171 0248_ $$2sideral$$a94468
000168171 037__ $$aART-1998-94468
000168171 041__ $$aeng
000168171 100__ $$0(orcid)0000-0003-0076-3529$$aGomollón, F$$uUniversidad de Zaragoza
000168171 245__ $$aThe ideal therapy must be defined in each geographical area: experience with a quadruple therapy in Spain
000168171 260__ $$c1998
000168171 5060_ $$aAccess copy available to the general public$$fUnrestricted
000168171 5203_ $$aBACKGROUND: Multiple therapeutic combinations have been tested to determine the optimal regimen(s) for Helicobacter pylori eradication, leading to very different results depending on the geographical area. Our goal was to evaluate the efficacy of a "quadruple" therapy with omeprazole, tetracycline, bismuth and metronidazole in our area.
MATERIALS AND METHODS: We investigate 106 consecutive patients with active peptic ulcer disease (duodenal, gastric or both) and Helicobacter pylori infection. One-week therapy with omeprazole 20 mg b.i.d., tetracycline hydrochloride 500 mg q.i.d., colloidal bismuth subcitrate 120 mg q.i.d., and metronidazole 250 mg t.i.d was prescribed. Between the days 30 and 40 after treatment ended follow-up endoscopy was performed. Eradication was defined as both negative urease test and histology. Between days 90 and 360 a 13C urea breath test was performed in 100 patients.
RESULTS: Of the 106 patients in the study, 91 had duodenal ulcer, 12 had gastric ulcer, and 3 had both. Side effects were observed in 25% of the cases. Eradication was achieved in 87.7% (93/106; CI 79.9-93.3). Healing was obtained in 95.2% (100/105; CI 89.2-98.4); 97.8% (CI 92.4-99.7) in those eradicated and 75% (CI 42.8-94.5) in non-eradicated (p < .01).
CONCLUSIONS: Quadruple therapy with omeprazole, tetracycline, bismuth subcitrate and metronidazole achieves healing rates up to 95-100%. The 87.7% eradication rate obtained suggests that the regimen we used is a reasonable therapeutic alternative in our area.
000168171 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168171 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000168171 700__ $$aDucóns, JA
000168171 700__ $$0(orcid)0000-0003-2928-6623$$aGimeno, L
000168171 700__ $$0(orcid)0000-0001-8637-510X$$aFuentes, J
000168171 700__ $$0(orcid)0000-0003-3970-5457$$aGarcía López, S
000168171 700__ $$aVera, J
000168171 700__ $$aMontoro, M.
000168171 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina y Psiquiatr.$$cArea Medicina
000168171 773__ $$g3, 2 (1998), 110-114$$pHelicobacter$$tHELICOBACTER$$x1083-4389
000168171 8564_ $$s187848$$uhttps://zaguan.unizar.es/record/168171/files/texto_completo.pdf$$yPostprint
000168171 8564_ $$s512591$$uhttps://zaguan.unizar.es/record/168171/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000168171 909CO $$ooai:zaguan.unizar.es:168171$$particulos$$pdriver
000168171 951__ $$a2026-02-02-14:49:02
000168171 980__ $$aARTICLE